BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 30561604)

  • 1. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
    Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
    Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
    Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
    Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer.
    Porcu E; Cillo GM; Cipriani L; Sacilotto F; Notarangelo L; Damiano G; Dirodi M; Roncarati I
    J Assist Reprod Genet; 2020 Mar; 37(3):709-715. PubMed ID: 31872386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
    Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
    Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
    Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
    Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
    Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
    Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation.
    Raad J; Sonigo C; Benoit A; Cedrin-Durnerin I; Sifer C; Sermondade N; Grynberg M
    Hum Reprod; 2022 Jun; 37(7):1480-1488. PubMed ID: 35586947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
    Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
    Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
    Turan V; Oktay K
    Hum Reprod Update; 2020 Jan; 26(1):43-57. PubMed ID: 31822904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
    Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
    Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
    Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
    Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
    Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study.
    Delattre S; Segers I; Van Moer E; Drakopoulos P; Mateizel I; Enghels L; Tournaye H; De Vos M
    Hum Reprod; 2020 Nov; 35(11):2524-2536. PubMed ID: 32951035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI.
    Mostinckx L; Goyens E; Mackens S; Roelens C; Boudry L; Uvin V; Segers I; Schoemans C; Drakopoulos P; Blockeel C; De Vos M
    Hum Reprod; 2024 Mar; 39(3):586-594. PubMed ID: 38177084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
    Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
    Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.
    Malacarne E; Devesa M; Martinez F; Rodriguez I; Coroleu B
    J Assist Reprod Genet; 2020 Dec; 37(12):3069-3076. PubMed ID: 32945994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human-induced pluripotent stem cell-derived ovarian support cell co-culture improves oocyte maturation in vitro after abbreviated gonadotropin stimulation.
    Piechota S; Marchante M; Giovannini A; Paulsen B; Potts KS; Rockwell G; Aschenberger C; Noblett AD; Figueroa AB; Sanchez M; Barrachina F; Wiemer K; Guzman L; Belchin P; Pierson Smela M; Fortuna PRJ; Chatterjee P; Tran ND; Kelk DA; Forti M; Marcinyshyn S; Smith T; McCulloh DH; Fernandez-Gonzalez MJ; Abittan B; Ortiz S; Klein JU; Klatsky P; Ordonez-Perez D; Kramme CC
    Hum Reprod; 2023 Dec; 38(12):2456-2469. PubMed ID: 37815487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.
    Derks-Smeets IAP; van Tilborg TC; van Montfoort A; Smits L; Torrance HL; Meijer-Hoogeveen M; Broekmans F; Dreesen JCFM; Paulussen ADC; Tjan-Heijnen VCG; Homminga I; van den Berg MMJ; Ausems MGEM; de Rycke M; de Die-Smulders CEM; Verpoest W; van Golde R
    J Assist Reprod Genet; 2017 Nov; 34(11):1475-1482. PubMed ID: 28831696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Lambertini M; Goldrat O; Ferreira AR; Dechene J; Azim HA; Desir J; Delbaere A; t'Kint de Roodenbeke MD; de Azambuja E; Ignatiadis M; Demeestere I
    Ann Oncol; 2018 Jan; 29(1):237-243. PubMed ID: 29045555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.